ClinicalTrials.gov posted results on 2026-08-07 for NCT05243862, a completed phase 2 study of atezolizumab with PolyPEPI1018 in metastatic colorectal cancer. The multicenter, open-label trial enrolled 18 participants with MSS colorectal cancer who had progressed on 2 or 3 prior regimens.
Background
The record describes a combination study of atezolizumab and PolyPEPI1018 in colorectal cancer metastatic. The posted brief summary says the trial was designed to assess safety, tolerability, immunogenicity, and initial clinical activity in participants with MSS colorectal cancer.
Trial design
This was a multicenter, open-label phase II trial. Participants received PolyPEPI1018 plus atezolizumab, and the study focused on safety and early activity in a heavily pretreated population.
Key results
The posted results list treatment-related adverse event counts of 18 participants, 17 participants, 14 participants, 4 participants, 1 participant, 4 participants, 0 participants, 0 participants, 3 participants, 0 participants, and 2 participants in the PolyPEPI1018 plus atezolizumab group. For clinical laboratory safety, the record reports 0 participants.
What this means
These posted results add a completed phase 2 data point for an atezolizumab-based combination in metastatic colorectal cancer after prior regimens. The record supports a safety-focused readout, but the dataset provided here does not include efficacy endpoints, response rates, or statistical testing.
Source
This information is based on ClinicalTrials.gov trial results for NCT05243862 posted on 2026-08-07. The record is available at clinicaltrials.gov.